RxDoctor Payments Data

Arveen Bhasin, MD

Allergy & Immunology · Jacksonville, FLNPI 1376641183

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AstraZeneca at 36.5% of the total. That places this record below the midpoint for allergy & immunology clinicians in FL, where the typical reported total is $5,220.

$1,027in general payments, 2019–2025

Across 12 payments — averaging $85.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$375
  • Regeneron Healthcare Solutions, Inc.$328
  • GSK$230
  • Lilly USA, LLC$94
$31,866in research payments, 2019–2025

Across 4 payments — averaging $7966.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$32K

What the payments were for

  • Food & beverage$1,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,027 in reported general payments places this provider in the 25th percentile of 204 allergy & immunology providers in Florida.

See all allergy & immunology providers in Florida

Medicare billing

Part B allowed, 2024
$417,286
Medicare patients
204
Services billed
14,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo11$282,844
XolairOmalizumab31$146,852
NucalaMepolizumab29$121,779
IcatibantIcatibant Acetate18$48,749
Pulmicort FlexhalerBudesonide19$5,154
Epinephrine13$3,574
Ipratropium Bromide12$533
Montelukast Sodium34$394
Prednisone11$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala$230$121,77929 claims
AstraZenecaPulmicort Flexhaler$375$5,15419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 204 allergy & immunology providers in Florida.

Other allergy & immunology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →